Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse-Reference-Cited by-同舟云学术

Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse

Published:2024-01-17 Issue:2 Volume:119 Page:164-172
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Akimoto Masahiro,Miyazaki Takuya^ORCID,Takahashi Hiroyuki,Saigusa Yusuke,Takeda Takaaki,Hibino Yuto,Tokunaga Mayumi,Ohashi Takuma,Matsumura Ayako,Teshigawara Haruka,Suzuki Taisei,Teranaka Hiroshi,Nakajima Yuki,Matsumoto Kenji,Hashimoto Chizuko,Fujimaki Katsumichi,Fujita Hiroyuki,Sakai Rika,Fujisawa Shin,Nakajima Hideaki

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12185-023-03700-0.pdf

Reference32 articles.

1. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–6.

2. Roschewski M. Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom. Haematologica. 2021;106:332–4.

3. Qualls D, Abramson JS. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2019;104:25–34.

4. El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68.

5. Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130:867–74.